Atrial Fibrillation Data For Boehringer Ingelheim’s Dabigatran Due In Early 2009
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm completes enrollment in RE-LY trial, one of seven in the Phase III RE-VOLUTION program for the investigational antithrombotic.
You may also be interested in...
Learning From Exanta: AstraZeneca Ready For Phase III With ‘0837
With its once-daily oral anticoagulant AZD0837 ready to move into Phase III, AstraZeneca is talking up the lessons it learned from its experience with the failed anticoagulantExanta (ximelagatran)
Learning From Exanta: AstraZeneca Ready For Phase III With ‘0837
With its once-daily oral anticoagulant AZD0837 ready to move into Phase III, AstraZeneca is talking up the lessons it learned from its experience with the failed anticoagulantExanta (ximelagatran)
Boehringer Ingelheim’s Dabigatran Demonstrates Non-Inferiority To Lovenox
The drug maker is in discussions with U.S. regulators regarding submission for venous thromboembolism, but has not released a filing timeline.